表紙
市場調查報告書

活病毒疫苗的市場預測 2020-2030年:細菌,病毒,口服小兒麻庳疫苗,麻疹,輪狀病毒,結核,黃熱病

Global Live Vaccines Market Forecast 2020-2030: Bacterial, Viral, Oral Polio Vaccine, Measles, Rotavirus, Tuberculosis, Yellow Fever, Oral, Injectable, End Users, Hospitals, Specialty Clinics, Others

出版商 Visiongain Ltd 商品編碼 935841
出版日期 內容資訊 英文 213 Pages
商品交期: 最快1-2個工作天內
價格
活病毒疫苗的市場預測 2020-2030年:細菌,病毒,口服小兒麻庳疫苗,麻疹,輪狀病毒,結核,黃熱病 Global Live Vaccines Market Forecast 2020-2030: Bacterial, Viral, Oral Polio Vaccine, Measles, Rotavirus, Tuberculosis, Yellow Fever, Oral, Injectable, End Users, Hospitals, Specialty Clinics, Others
出版日期: 2020年03月12日內容資訊: 英文 213 Pages
簡介

全球活病毒疫苗市場在2019年估算為104億2340萬美元,至2030年預計將超越200億2000萬美元的規模。2019年,北美市場區隔佔全球活病毒疫苗市場39%。

本報告提供全球活病毒疫苗市場相關調查,各市場區隔及各地區的市場分析與預測,市場發展的影響要素,競爭環境,及主要企業等相關的系統性資訊。

第1章 報告概要

第2章 活病毒疫苗的簡介

  • 活病毒疫苗是什麼?
  • 減毒活病毒疫苗的優點與缺點
  • WHO推薦使用了LAV科技的疫苗
  • 疫苗開發現況
  • 聯邦機關所扮演的角色
  • 醫藥品開發及核准流程
  • 社會及經濟負擔

第3章 市場概要

  • 市場結構
  • 各類型分類
    • 細菌
    • 病毒
  • 各適應症分類
    • 口服小兒麻庳疫苗(OPV)
    • 麻疹
    • 輪狀病毒
    • 結核
    • 黃熱病
    • 其他
  • 各給藥途徑分類
    • 口服
    • 注射劑
  • 各終端用戶分類

第4章 全球活病毒疫苗市場

  • 全球活病毒疫苗市場
  • 全球活病毒疫苗市場預測
  • 全球活病毒疫苗:各類型
  • 全球活病毒疫苗:各適應症
  • 全球活病毒疫苗:各給藥途徑
  • 全球活病毒疫苗:各終端用戶

第5章 主要國家市場預測

  • 全球活病毒疫苗市場:各地區明細
    • 全球活病毒疫苗市場:各地區明細
    • 全球活病毒疫苗市場:各國明細
  • 全球活病毒疫苗市場:各地區預測
  • 北美的活病毒疫苗市場
    • 美國的活病毒疫苗市場預測
    • 加拿大的活病毒疫苗市場預測
  • 歐洲的活病毒疫苗市場
    • 德國的活病毒疫苗市場預測
    • 法國的活病毒疫苗市場預測
    • 英國的活病毒疫苗市場預測
    • 義大利的活病毒疫苗市場預測
    • 西班牙的活病毒疫苗市場預測
    • 其他歐洲的活病毒疫苗市場預測
  • 亞太地區活病毒疫苗市場
    • 日本的活病毒疫苗市場預測
    • 中國的活病毒疫苗市場預測
    • 印度的活病毒疫苗市場預測
    • 其他亞太地區各國的活病毒疫苗市場預測
  • 南美的活病毒疫苗市場,
    • 巴西的活病毒疫苗市場預測
    • 墨西哥的活病毒疫苗市場預測
    • 其他南美國家的活病毒疫苗市場預測
  • 中東、非洲的活病毒疫苗市場
    • GCC的活病毒疫苗市場預測
    • 南非的活病毒疫苗市場預測
    • 其他MEA的活病毒疫苗市場預測

第6章 全球活病毒疫苗市場上定性分析

  • 全球活病毒疫苗市場上SWOT分析
    • 優勢
    • 弱點
    • 市場機會
    • 威脅
  • PEST分析
  • 市場趨勢
  • 市場成長要素
    • 疫苗開發的投資的增加
    • 高的感染疾病盛行率
    • 劇增的調查開發活動
    • 對疫苗接種計劃的政府的關注高漲
  • 市場阻礙因素
    • 醫療費償付不足
    • 疫苗製造需要長期的時間軸
    • 產品的認證相關的嚴格政府法規
  • 市場課題
    • 對疫苗的獲取不足
    • 產品的回收
  • 市場機會
    • 來自新興國家的需求高漲

第7章 全球活病毒疫苗市場上主要企業

  • Sanofi
  • Emergent BioSolutions Inc.
  • GlaxoSmithKline plc
  • Pfizer Inc.
  • Merck & Co., Inc.
  • 第一三共
  • Inovio Pharmaceuticals, Inc.
  • Serum Institute of India
  • Bavarian Nordic
  • 田邊三菱製藥
  • AstraZeneca
  • Vivaldi Biosciences Inc.

第8章 結論

第9章 詞彙表

目錄
Product Code: PHA0725

The global live vaccines market was valued at $10,423.4 mn in 2019 and is anticipated to surpass $ 20,020 mn by 2030. In 2019, the North American segment held 39% of the global live vaccines market.

How this report will benefit you

Read on to discover how you can exploit the future business opportunities emerging in this sector.

In this brand new 213-page report you will receive 138 tables and 65 figures- all unavailable elsewhere.

The 213-page report provides clear detailed insight into the live vaccines market. Discover the key drivers and challenges affecting the market.

By ordering and reading our brand-new report today you stay better informed and ready to act.

Report Scope:

Global Live Vaccines Market from 2020-2030.

Forecast of the Global Live Vaccines Market by Type of Product:

  • Bacterial
  • Viral

Forecast of the Global Live Vaccines Market by Indication:

  • Oral Polio Vaccine (OPV)
  • Measles
  • Rotavirus
  • Tuberculosis
  • Yellow Fever
  • Others

This report provides individual revenue forecasts to 2030 for these national markets:

  • The US
  • Canada
  • Germany
  • France
  • UK
  • Italy
  • Spain
  • Japan
  • China
  • India
  • Brazil
  • Mexico

Our study discusses the selected leading companies that are the major players in the live vaccines market:

  • AstraZeneca
  • Bavarian Nordic A/S
  • DAIICHI SANKYO COMPANY, LIMITED
  • Emergent BioSolutions Inc.
  • GlaxoSmithKline plc
  • Inovio Pharmaceuticals, Inc.
  • & Other Companies

This report discusses factors that drive and restrain this market. As well as opportunities and challenges faced by this market.

This report discusses the SWOT & PEST Analyses of the live vaccines market.

Visiongain's study is intended for anyone requiring commercial analyses for the live vaccines market. You find data, trends and predictions.

Buy our report today Global Live Vaccines Market Forecast 2020-2030: Bacterial, Viral, Oral Polio Vaccine, Measles, Rotavirus, Tuberculosis, Yellow Fever, Oral, Injectable, End Users, Hospitals, Specialty Clinics, Others.

Visiongain is a trading partner with the US Federal Government.

Table of Contents

1. Report Overview

  • 1.1 Why You Should Read This Report
  • 1.2 How This Report Delivers
  • 1.3 Key Questions Answered by This Analytical Report:
  • 1.4 Who is This Report for?
  • 1.5 Methodology
    • 1.5.1 Primary Research
    • 1.5.2 Secondary Research
    • 1.5.3 Market Evaluation & Forecasting Methodology
  • 1.6 Frequently Asked Questions
  • 1.7 Associated Reports
  • 1.8 About Visiongain

2. Introduction to Live Vaccines

  • 2.1 What are Live Vaccines?
  • 2.2 Pros and Cons of Live, Attenuated Vaccines
  • 2.3 WHO recommended vaccines using LAV Technology
  • 2.4 Current Status of Vaccine Development
  • 2.5 Role of Federal Agencies
  • 2.6 Drug Development and Approval Process
  • 2.7 Social and Economic Burden

3. Market Overview

  • 3.1 Market Structure
  • 3.2 Classification by Type
    • 3.2.1 Bacterial
    • 3.2.2 Viral
  • 3.3 Classification by Indication
    • 3.3.1 Oral Polio Vaccine (OPV)
    • 3.3.2 Measles
    • 3.3.3 Rotavirus
    • 3.3.4 Tuberculosis
    • 3.3.5 Yellow Fever
    • 3.3.6 Others
  • 3.4 Classification by Route of Administration
    • 3.4.1 Oral
    • 3.4.2 Injectable
  • 3.5 Classification by End Users

4. Global Live Vaccines Market, 2020-2030

  • 4.1 Global Live Vaccines Market, 2019
  • 4.2 Global Live Vaccines Market Forecast, 2020-2030
  • 4.3 Global Live Vaccines by Type
    • 4.3.1 Global Live Vaccines by Type: Market Forecasts 2020-2030
  • 4.4 Global Live Vaccines by Indication
    • 4.4.1 Global Live Vaccines by Indication: Market Forecasts 2020-2030
  • 4.5 Global Live Vaccines by Route of Administration
    • 4.5.1 Global Live Vaccines by Route of Administration: Market Forecasts 2020-2030
  • 4.6 Global Live Vaccines by End User
    • 4.6.1 Global Live Vaccines by End User: Market Forecasts 2020-2030

5. Leading National Markets Forecast 2020-2030

  • 5.1 Geographical Breakdown of Global Live Vaccines Market, 2019
    • 5.1.1 Regional Breakdown of Global Live Vaccines Market, 2019
    • 5.1.2 Country Breakdown of Global Live Vaccines Market, 2020
  • 5.2 Regional Forecast of Global Live Vaccines Market, 2019-2030
  • 5.3 North America Live Vaccines Market, 2020-2030
    • 5.3.1 U.S. Live Vaccines Market Forecast, 2020-2030
    • 5.3.2 Canada Live Vaccines Market Forecast, 2020-2030
  • 5.4 Europe Live Vaccines Market, 2020-2030
    • 5.4.1 Germany Live Vaccines Market Forecast, 2020-2030
    • 5.4.2 France Live Vaccines Market Forecast, 2020-2030
    • 5.4.3 UK Live Vaccines Market Forecast, 2020-2030
    • 5.4.4 Italy Live Vaccines Market Forecast, 2020-2030
    • 5.4.5 Spain Live Vaccines Market Forecast, 2020-2030
    • 5.5.6 Rest of Europe Live Vaccines Market Forecast, 2020-2030
  • 5.5 Asia Pacific Live Vaccines Market, 2020-2030
    • 5.5.1 Japan Live Vaccines Market Forecast, 2020-2030
    • 5.5.2 China Live Vaccines Market Forecast, 2020-2030
    • 5.5.3 India Live Vaccines Market Forecast, 2020-2030
    • 5.5.4 Rest of APAC Live Vaccines Market Forecast, 2020-2030
  • 5.6 Latin America Live Vaccines Market, 2020-2030
    • 5.6.1 Brazil Live Vaccines Market Forecast, 2020-2030
    • 5.6.2 Mexico Live Vaccines Market Forecast, 2020-2030
    • 5.6.3 Rest of Latin America Live Vaccines Market Forecast, 2020-2030
  • 5.7 MEA Live Vaccines Market, 2020-2030
    • 5.7.1 GCC Countries Live Vaccines Market Forecast, 2020-2030
    • 5.7.2 South Africa Live Vaccines Market Forecast, 2020-2030
    • 5.7.3 Rest of MEA Live Vaccines Market Forecast, 2020-2030

6. Qualitative Analysis of the Global Live Vaccines Market

  • 6.1 SWOT Analysis of Global Live Vaccines Market
    • 6.1.1 Strengths
    • 6.1.2 Weakness
    • 6.1.3 Opportunities
    • 6.1.4 Threats
  • 6.2 PEST Analysis
  • 6.3 Market Trends
  • 6.4 Market Drivers
    • 6.4.1 Growing investment in vaccine development
    • 6.4.2 High prevalence of infectious diseases
    • 6.4.3 Rising Research and Development Activities
    • 6.4.4 Increase in Government Focus on Immunization Programs
  • 6.5 Market Restraints
    • 6.5.1 Inadequate Reimbursement Coverage
    • 6.5.2 Longer timelines required for Vaccine Production
    • 6.5.3 Stringent Government Regulations for the Approval of Products
  • 6.6 Market Challenges
    • 6.6.1 Inadequate Access to Vaccines
    • 6.6.2 Product Recalls
  • 6.7 Market Opportunities
    • 6.7.1 Growing demand from emerging economies

7. Leading Companies in Global Live Vaccines Market, 2020

  • 7.1 Sanofi
  • 7.2 Emergent BioSolutions Inc.
  • 7.3 GlaxoSmithKline plc
  • 7.4 Pfizer Inc.
  • 7.5 Merck & Co., Inc.
  • 7.6 DAIICHI SANKYO COMPANY, LIMITED
  • 7.7 Inovio Pharmaceuticals, Inc.
  • 7.8 Serum Institute of India
  • 7.9 Bavarian Nordic
  • 7.10 Mitsubishi Tanabe Pharma Corporation
  • 7.11 AstraZeneca
  • 7.12 Vivaldi Biosciences Inc.

8. Conclusions

9. Glossary

  • Associated Visiongain Reports
  • Visiongain Report Sales Order Form
  • About Visiongain
  • Visiongain report evaluation form

List of Tables

  • Table 4.1 Global Live Vaccines Market by Sub-Markets: Revenue ($m), and Market Share (%), 2019
  • Table 4.2 Global Live Vaccines Market Forecast 2019-2030: Revenue ($m), AGR (%), CAGR (%)
  • Table 4.3 Global Live Vaccines Market Forecast by Type, 2019-2030: Revenue ($m), AGR (%), CAGR (%)
  • Table 4.4 Global Live Vaccines Market by Type 2020-2030: AGR (%)
  • Table 4.5 Global Live Vaccines Market Forecast by Indication, 2019-2030: Revenue ($m), AGR (%), CAGR (%)
  • Table 4.6 Global Live Vaccines Market by Indication 2020-2030: AGR (%)
  • Table 4.7 Global Live Vaccines Market Forecast by Route of Administration, 2019-2030: Revenue ($m), AGR (%), CAGR (%)
  • Table 4.8 Global Live Vaccines Market by Type 2020-2030: AGR (%)
  • Table 4.9 Global Live Vaccines Market Forecast by End User, 2019-2030: Revenue ($m), AGR (%), CAGR (%)
  • Table 4.10 Global Live Vaccines Market by End User 2020-2030: AGR (%)
  • Table 5.1 Global Live Vaccines Market by Region: Revenue ($m), and Market Share (%), 2019
  • Table 5.2 Global Live Vaccines Market by Country: Revenue ($m), and Market Share (%), 2019
  • Table 5.3 Global Live Vaccines Market Forecast by Region, 2019-2030: Revenue ($m), AGR (%), CAGR (%)
  • Table 5.4 North America Live Vaccines Market by Country: Revenue ($m), and Market Share (%), 2019
  • Table 5.5 North America Live Vaccines Market Forecast by Type, 2019-2030: Revenue ($m), AGR (%), CAGR (%)
  • Table 5.6 North America Live Vaccines Market Forecast by Indication, 2019-2030: Revenue ($m), AGR (%), CAGR (%)
  • Table 5.7 North America Live Vaccines Market Forecast by Route of Administration, 2019-2030: Revenue ($m), AGR (%), CAGR (%)
  • Table 5.8 North America Live Vaccines Market Forecast by End User, 2019-2030: Revenue ($m), AGR (%), CAGR (%)
  • Table 5.9 U.S. Live Vaccines Market Forecast by Type, 2019-2030: Revenue ($m), AGR (%), CAGR (%)
  • Table 5.10 U.S. Live Vaccines Market Forecast by Indication, 2019-2030: Revenue ($m), AGR (%), CAGR (%)
  • Table 5.11 U.S. Live Vaccines Market Forecast by Route of Administration, 2019-2030: Revenue ($m), AGR (%), CAGR (%)
  • Table 5.12 U.S. Live Vaccines Market Forecast by End User, 2019-2030: Revenue ($m), AGR (%), CAGR (%)
  • Table 5.13 Canada Live Vaccines Market Forecast by Type, 2019-2030: Revenue ($m), AGR (%), CAGR (%)
  • Table 5.14 Canada Live Vaccines Market Forecast by Indication, 2019-2030: Revenue ($m), AGR (%), CAGR (%)
  • Table 5.15 Canada Live Vaccines Market Forecast by Route of Administration, 2019- 2030: Revenue ($m), AGR (%), CAGR (%)
  • Table 5.16 Canada Live Vaccines Market Forecast by End User, 2019-2030: Revenue ($m), AGR (%), CAGR (%)
  • Table 5.17 Europe Live Vaccines Market by Country: Revenue ($m), and Market Share (%), 2019
  • Table 5.18 Europe Live Vaccines Market Forecast by Type, 2019-2030: Revenue ($m), AGR (%), CAGR (%)
  • Table 5.19 Europe Live Vaccines Market Forecast by Indication, 2019-2030: Revenue ($m), AGR (%), CAGR (%)
  • Table 5.20 Europe Live Vaccines Market Forecast by Route of Administration, 2019-2030: Revenue ($m), AGR (%), CAGR (%)
  • Table 5.21 Europe Live Vaccines Market Forecast by End User, 2019-2030: Revenue ($m), AGR (%), CAGR (%)
  • Table 5.22 Germany Live Vaccines Market Forecast by Type, 2019-2030: Revenue ($m), AGR (%), CAGR (%)
  • Table 5.23 Germany Live Vaccines Market Forecast by Indication, 2019-2030: Revenue ($m), AGR (%), CAGR (%)
  • Table 5.24 Germany Live Vaccines Market Forecast by Route of Administration, 2019- 2030: Revenue ($m), AGR (%), CAGR (%)
  • Table 5.25 Germany Live Vaccines Market Forecast by End User, 2019-2030: Revenue ($m), AGR (%), CAGR (%)
  • Table 5.26 France Live Vaccines Market Forecast by Type, 2019-2030: Revenue ($m), AGR (%), CAGR (%)
  • Table 5.27 France Live Vaccines Market Forecast by Indication, 2019-2030: Revenue ($m), AGR (%), CAGR (%)
  • Table 5.28 France Live Vaccines Market Forecast by Route of Administration, 2019-2030: Revenue ($m), AGR (%), CAGR (%)
  • Table 5.29 France Live Vaccines Market Forecast by End User, 2019-2030: Revenue ($m), AGR (%), CAGR (%)
  • Table 5.30 UK Live Vaccines Market Forecast by Type, 2019-2030: Revenue ($m), AGR (%), CAGR (%)
  • Table 5.31 UK Live Vaccines Market Forecast by Indication, 2019-2030: Revenue ($m), AGR (%), CAGR (%)
  • Table 5.32 UK Live Vaccines Market Forecast by Route of Administration, 2019-2030: Revenue ($m), AGR (%), CAGR (%)
  • Table 5.33 UK Live Vaccines Market Forecast by End User, 2019-2030: Revenue ($m), AGR (%), CAGR (%)
  • Table 5.34 Italy Live Vaccines Market Forecast by Type, 2019-2030: Revenue ($m), AGR (%), CAGR (%)
  • Table 5.35 Italy Live Vaccines Market Forecast by Indication, 2019-2030: Revenue ($m), AGR (%), CAGR (%)
  • Table 5.36 Italy Live Vaccines Market Forecast by Route of Administration, 2019-2030: Revenue ($m), AGR (%), CAGR (%)
  • Table 5.37 Italy Live Vaccines Market Forecast by End User, 2019-2030: Revenue ($m), AGR (%), CAGR (%)
  • Table 5.38 Spain Live Vaccines Market Forecast by Type, 2019-2030: Revenue ($m), AGR (%), CAGR (%)
  • Table 5.39 Spain Live Vaccines Market Forecast by Indication, 2019-2030: Revenue ($m), AGR (%), CAGR (%)
  • Table 5.40 Spain Live Vaccines Market Forecast by Route of Administration, 2019-2030: Revenue ($m), AGR (%), CAGR (%)
  • Table 5.41 Spain Live Vaccines Market Forecast by End User, 2019-2030: Revenue ($m), AGR (%), CAGR (%)
  • Table 5.42 Rest of Europe Live Vaccines Market Forecast by Type, 2019-2030: Revenue ($m), AGR (%), CAGR (%)
  • Table 5.43 Rest of Europe Live Vaccines Market Forecast by Indication, 2019-2030: Revenue ($m), AGR (%), CAGR (%)
  • Table 5.44 Rest of Europe Live Vaccines Market Forecast by Route of Administration, 2019-2030: Revenue ($m), AGR (%), CAGR (%)
  • Table 5.45 Rest of Europe Live Vaccines Market Forecast by End User, 2019-2030: Revenue ($m), AGR (%), CAGR (%)
  • Table 5.46 Asia Pacific Live Vaccines Market by Country: Revenue ($m), and Market Share (%), 2019
  • Table 5.47 Asia Pacific Live Vaccines Market Forecast by Type, 2019-2030: Revenue ($m), AGR (%), CAGR (%)
  • Table 5.48 Asia Pacific Live Vaccines Market Forecast by Indication, 2019-2030: Revenue ($m), AGR (%), CAGR (%)
  • Table 5.49 Asia Pacific Live Vaccines Market Forecast by Route of Administration, 2019- 2030: Revenue ($m), AGR (%), CAGR (%)
  • Table 5.50 Asia Pacific Live Vaccines Market Forecast by End User, 2019-2030: Revenue ($m), AGR (%), CAGR (%)
  • Table 5.51 Japan Live Vaccines Market Forecast by Type, 2019-2030: Revenue ($m), AGR (%), CAGR (%)
  • Table 5.52 Japan Live Vaccines Market Forecast by Indication, 2019-2030: Revenue ($m), AGR (%), CAGR (%)
  • Table 5.53 Japan Live Vaccines Market Forecast by Route of Administration, 2019-2030: Revenue ($m), AGR (%), CAGR (%)
  • Table 5.54 Japan Live Vaccines Market Forecast by End User, 2019-2030: Revenue ($m), AGR (%), CAGR (%)
  • Table 5.55 China Live Vaccines Market Forecast by Type, 2019-2030: Revenue ($m), AGR (%), CAGR (%)
  • Table 5.56 China Live Vaccines Market Forecast by Indication, 2019-2030: Revenue ($m), AGR (%), CAGR (%)
  • Table 5.57 China Live Vaccines Market Forecast by Route of Administration, 2019-2030: Revenue ($m), AGR (%), CAGR (%)
  • Table 5.58 China Live Vaccines Market Forecast by End User, 2019-2030: Revenue ($m), AGR (%), CAGR (%)
  • Table 5.59 India Live Vaccines Market Forecast by Type, 2019-2030: Revenue ($m), AGR (%), CAGR (%)
  • Table 5.60 India Live Vaccines Market Forecast by Indication, 2019-2030: Revenue ($m), AGR (%), CAGR (%)
  • Table 5.61 India Live Vaccines Market Forecast by Route of Administration, 2019-2030: Revenue ($m), AGR (%), CAGR (%)
  • Table 5.62 India Live Vaccines Market Forecast by End User, 2019-2030: Revenue ($m), AGR (%), CAGR (%)
  • Table 5.63 Rest of APAC Live Vaccines Market Forecast by Type, 2019-2030: Revenue ($m), AGR (%), CAGR (%)
  • Table 5.64 Rest of APAC Live Vaccines Market Forecast by Indication, 2019-2030: Revenue ($m), AGR (%), CAGR (%)
  • Table 5.65 Rest of APAC Live Vaccines Market Forecast by Route of Administration, 2019-2030: Revenue ($m), CAGR (%)
  • Table 5.66 Rest of APAC Live Vaccines Market Forecast by End User, 2019-2030: Revenue ($m), CAGR (%)
  • Table 5.67 Latin America Live Vaccines Market by Country: Revenue ($m), and Market Share (%), 2019
  • Table 5.68 Latin America Live Vaccines Market Forecast by Type, 2019-2030: Revenue ($m), AGR (%), CAGR (%)
  • Table 5.69 Latin America Live Vaccines Market Forecast by Indication, 2019-2030: Revenue ($m), AGR (%), CAGR (%)
  • Table 5.70 Latin America Live Vaccines Market Forecast by Route of Administration, 2019-2030: Revenue ($m), AGR (%), CAGR (%)
  • Table 5.71 Latin America Live Vaccines Market Forecast by End User, 2019-2030: Revenue ($m), AGR (%), CAGR (%)
  • Table 5.72 Brazil Live Vaccines Market Forecast by Type, 2019-2030: Revenue ($m), AGR (%), CAGR (%)
  • Table 5.73 Brazil Live Vaccines Market Forecast by Indication, 2019-2030: Revenue ($m), AGR (%), CAGR (%)
  • Table 5.74 Brazil Live Vaccines Market Forecast by Route of Administration, 2019-2030: Revenue ($m), AGR (%), CAGR (%)
  • Table 5.75 Brazil Live Vaccines Market Forecast by End User, 2019-2030: Revenue ($m), AGR (%), CAGR (%)
  • Table 5.76 Mexico Live Vaccines Market Forecast by Type, 2019-2030: Revenue ($m), AGR (%), CAGR (%)
  • Table 5.77 Mexico Live Vaccines Market Forecast by Indication, 2019-2030: Revenue ($m), AGR (%), CAGR (%)
  • Table 5.78 Mexico Live Vaccines Market Forecast by Route of Administration, 2019-2030: Revenue ($m), AGR (%), CAGR (%)
  • Table 5.79 Mexico Live Vaccines Market Forecast by End User, 2019-2030: Revenue ($m), AGR (%), CAGR (%)
  • Table 5.80 Rest of Latin America Live Vaccines Market Forecast by Type, 2019-2030: Revenue ($m), AGR (%), CAGR (%)
  • Table 5.81 Rest of Latin America Live Vaccines Market Forecast by Indication, 2019- 2030: Revenue ($m), AGR (%), CAGR (%)
  • Table 5.82 Rest of Latin America Live Vaccines Market Forecast by Route of Administration, 2019-2030: Revenue ($m), AGR(%), CAGR (%)
  • Table 5.83 Rest of Latin America Live Vaccines Market Forecast by End User, 2019- 2030: Revenue ($m), AGR (%), CAGR (%)
  • Table 5.84 MEA Live Vaccines Market by Country: Revenue ($m), and Market Share (%), 2019
  • Table 5.85 MEA Live Vaccines Market Forecast by Type, 2019-2030: Revenue ($m), AGR (%), CAGR (%)
  • Table 5.86 MEA Live Vaccines Market Forecast by Indication, 2019-2030: Revenue ($m), AGR (%), CAGR (%)
  • Table 5.87 MEA Live Vaccines Market Forecast by Route of Administration, 2019-2030: Revenue ($m), AGR (%), CAGR (%)
  • Table 5.88 MEA Live Vaccines Market Forecast by End User, 2019-2030: Revenue ($m), AGR (%), CAGR (%)
  • Table 5.89 GCC Countries Live Vaccines Market Forecast by Type, 2019-2030: Revenue ($m), AGR (%), CAGR (%)
  • Table 5.90 GCC Countries Live Vaccines Market Forecast by Indication, 2019-2030: Revenue ($m), AGR (%), CAGR (%)
  • Table 5.91 GCC Countries Live Vaccines Market Forecast by Route of Administration, 2019-2030: Revenue ($m), AGR (%), CAGR (%)
  • Table 5.92 GCC Countries Live Vaccines Market Forecast by End User, 2019-2030: Revenue ($m), AGR (%), CAGR (%)
  • Table 5.93 South Africa Live Vaccines Market Forecast by Type, 2019-2030: Revenue ($m), AGR (%), CAGR (%)
  • Table 5.94 South Africa Live Vaccines Market Forecast by Indication, 2019-2030: Revenue ($m), AGR (%), CAGR (%)
  • Table 5.95 South Africa Live Vaccines Market Forecast by Route of Administration, 2019- 2030: Revenue ($m), AGR (%), CAGR (%)
  • Table 5.96 South Africa Live Vaccines Market Forecast by End User, 2019-2030: Revenue ($m), AGR (%), CAGR (%)
  • Table 5.97 Rest of MEA Live Vaccines Market Forecast by Type, 2019-2030: Revenue ($m), AGR (%), CAGR (%)
  • Table 5.98 Rest of MEA Live Vaccines Market Forecast by Indication, 2019-2030: Revenue ($m), AGR (%), CAGR (%)
  • Table 5.99 Rest of MEA Live Vaccines Market Forecast by Route of Administration, 2019- 2030: Revenue ($m), AGR (%), CAGR (%)
  • Table 5.100 Rest of MEA Live Vaccines Market Forecast by End User, 2019-2030: Revenue ($m), AGR (%), CAGR (%)
  • Table 7.1 Company: Snapshot
  • Table 7.2: Product/Pipeline
  • Table 7.3: Product/Pipeline
  • Table 7.4 Company: Snapshot
  • Table 7.5: Product/Pipeline
  • Table 7.6: Recent Developments
  • Table 7.7 Company: Snapshot
  • Table 7.8: Product/Pipeline
  • Table 7.9 Company: Snapshot
  • Table 7.10: Product/Pipeline
  • Table 7.11 Company: Snapshot
  • Table 7.12: Product/Pipeline
  • Table 7.13 Company: Snapshot
  • Table 7.14: Product/Pipeline
  • Table 7.15 Company: Snapshot
  • Table 7.16: Product/Pipeline
  • Table 7.17: Recent Developments
  • Table 7.18 Company: Snapshot
  • Table 7.19: Product/Pipeline
  • Table 7.20 Company: Snapshot
  • Table 7.21: Product/Pipeline
  • Table 7.22: Recent Developments
  • Table 7.23 Company: Snapshot
  • Table 7.24: Product/Pipeline
  • Table 7.25 Company: Snapshot
  • Table 7.26 Company: Product/Pipeline
  • Table 7.27 Company: Snapshot
  • Table 7.28: Product/Pipeline

List of Figures

  • Figure 2.1 Vaccine Types, WHO
  • Figure 3.1 Global Live Vaccines Market Segmentation Overview
  • Figure 3.2 Live Vaccines Classification by Type, 2020
  • Figure 3.3 Bacterial Market, 2019-2030 (Revenue: $mn)
  • Figure 3.4 Medical conditions associated with viral vaccines
  • Figure 3.5 Viral Market, 2019-2030 (Revenue: $mn)
  • Figure 3.6 Live Vaccines Classification by Indication, 2020
  • Figure 3.7 Global Vaccination Coverage, 1980-2018
  • Figure 3.8 Global Vaccination Coverage, 2010-2018
  • Figure 3.9 Global Vaccination Coverage, 2018
  • Figure 3.10 Deaths Caused by Vaccine-Preventable Diseases Globally, 2017
  • Figure 3.11 Supply History and Breakdown of OPV Vaccines and WAP Trend
  • Figure 3.12 OPV Market, 2019-2030 (Revenue: $mn)
  • Figure 3.13 Measles Market, 2019-2030 (Revenue: $mn)
  • Figure 3.14 Rotavirus Market, 2019-2030 (Revenue: $mn)
  • Figure 3.15 Share of One-Year-Olds Vaccinated Against Rotavirus
  • Figure 3.16 Tuberculosis Market, 2019-2030 (Revenue: $mn)
  • Figure 3.17 Yellow Fever Market, 2019-2030 (Revenue: $mn)
  • Figure 3.18 Others Market, 2019-2030 (Revenue: $mn)
  • Figure 3.19 Live Vaccines Classification by Route of Administration, 2020
  • Figure 3.20 Global Live Vaccines Market by Route of Administration, 2019-2030 (Revenue: $mn)
  • Figure 3.21 Oral Market, 2019-2030 (Revenue: $mn)
  • Figure 3.22 Injectable Market, 2019-2030 (Revenue: $mn)
  • Figure 3.23 Live Vaccines Classification by End Users, 2020
  • Figure 3.24 Global Live Vaccines Market by End Users, 2019-2030 (Revenue: $mn)
  • Figure 4.1 Global Live Vaccines Market by Type: Market Share (%), 2019
  • Figure 4.2 Global Live Vaccines Market by Indication: Market Share (%), 2019
  • Figure 4.3 Global Live Vaccines Market by Route of Administration: Market Share (%), 2019
  • Figure 4.4 Global Live Vaccines Market by End User: Market Share (%), 2019
  • Figure 4.5 Global Live Vaccines Market by Region: Market Share (%), 2019
  • Figure 4.6 Global Live Vaccines Market Forecast 2019-2030: Revenue ($m), AGR (%)
  • Figure 4.7 Global Live Vaccines Market by Type: Market Share (%), 2020
  • Figure 4.8 Global Live Vaccines Market by Type: Market Share (%), 2025
  • Figure 4.9 Global Live Vaccines Market by Type: Market Share (%), 2030
  • Figure 4.10 Global Live Vaccines Market by Indication: Market Share (%), 2020
  • Figure 4.11 Global Live Vaccines Market by Indication: Market Share (%), 2025
  • Figure 4.12 Global Live Vaccines Market by Indication: Market Share (%), 2030
  • Figure 4.13 Global Live Vaccines Market by Route of Administration: Market Share (%), 2020
  • Figure 4.14 Global Live Vaccines Market by Route of Administration: Market Share (%), 2025
  • Figure 4.15 Global Live Vaccines Market by Route of Administration: Market Share (%), 2030
  • Figure 4.16 Global Live Vaccines Market by End User: Market Share (%), 2020
  • Figure 4.17 Global Live Vaccines Market by End User: Market Share (%), 2025
  • Figure 4.18 Global Live Vaccines Market by End User: Market Share (%), 2030
  • Figure 5.1 Global Live Vaccines Market Segmentation by Region/Country
  • Figure 5.2 Global Live Vaccines Market by Country: Market Share (%), 2020
  • Figure 5.3 Global Live Vaccines Market by Country: Market Share (%), 2025
  • Figure 5.4 Global Live Vaccines Market by Country: Market Share (%), 2030
  • Figure 5.5 North America Live Vaccines Market by Country: Market Share (%), 2020
  • Figure 5.6 North America Live Vaccines Market by Country: Market Share (%), 2025
  • Figure 5.7 North America Live Vaccines Market by Country: Market Share (%), 2030
  • Figure 5.8 Europe Live Vaccines Market by Country: Market Share (%), 2020
  • Figure 5.9 Europe Live Vaccines Market by Country: Market Share (%), 2025
  • Figure 5.10 Europe Live Vaccines Market by Country: Market Share (%), 2030
  • Figure 5.11 Asia Pacific Live Vaccines Market by Country: Market Share (%), 2020
  • Figure 5.12 Asia Pacific Live Vaccines Market by Country: Market Share (%), 2025
  • Figure 5.13 Asia Pacific Live Vaccines Market by Country: Market Share (%), 2030
  • Figure 5.14 Latin America Live Vaccines Market by Country: Market Share (%), 2020
  • Figure 5.15 Latin America Live Vaccines Market by Country: Market Share (%), 2025
  • Figure 5.16 Latin America Live Vaccines Market by Country: Market Share (%), 2030
  • Figure 5.17 MEA Live Vaccines Market by Country: Market Share (%), 2020
  • Figure 5.18 MEA Live Vaccines Market by Country: Market Share (%), 2025
  • Figure 5.19 MEA Live Vaccines Market by Country: Market Share (%), 2030
  • Figure 6.1 SWOT Analysis of the Global Live Vaccines Market
  • Figure 6.2 PEST Analysis of the Global Live Vaccines Market
  • Figure 6.3 Market Trends Analysis of the Global Live Vaccines Market

List of Companies Mentioned in the Report:

  • AstraZeneca
  • Bavarian Nordic A/S
  • DAIICHI SANKYO COMPANY, LIMITED
  • Emergent BioSolutions Inc.
  • GlaxoSmithKline plc
  • Inovio Pharmaceuticals, Inc.
  • Merck & Co., Inc.
  • Mitsubishi Tanabe Pharma Corporation
  • Pfizer
  • Sanofi
  • Serum Institute of India
  • Vivaldi Biosciences Inc.
  • List of Organisations Mentioned in the Report
  • Advisory Committee on Immunization Practices (ACIP)
  • American Academy of Family Physicists (AAFP)
  • American Academy of Pediatrics (AAP)
  • American College of Obstetricians and Gynecologists (ACOG)
  • American College of Physicians (ACP),
  • American Immunization Registry Association
  • Biomedical Advanced Research and Development Authority
  • Centers for Disease Control and Prevention (CDC)
  • Centers for Medicare & Medicaid Services (CMS).
  • Centre for Biologics Evaluation and Research (CBER)
  • GAVI
  • IDSA
  • Immunization Action Coalition
  • Institutional Review Board (IRB
  • International Vaccine Institute
  • National Center for Immunization and Respiratory Diseases
  • National Institutes of Health (NIH)
  • National Vaccine Information Center
  • Pan American Health Organization (PAHO)
  • Pharmaceutical Research and Manufacturers Association of America (PhRMA)
  • Public Health Agency of Canada
  • Strategic Advisory Group of Experts (SAGE)
  • The Global Polio Eradication Initiative
  • The International Federation of Red Cross and Red Crescent Societies
  • The United Nations Children's Fund
  • U.S. Department of Health and Human Services (HHS)
  • U.S. Food & Drug Administration
  • UNICEF
  • Universal Immunisation Programme (India)
  • VAERS (Vaccine Adverse Event Reporting System)
  • World Health Organization (WHO)